期刊文献+

Design and Synthesis of Tri-substituted Chiral Pyrrolidin-2-one Derivatives as CCR4 Antagonists

Design and Synthesis of Tri-substituted Chiral Pyrrolidin-2-one Derivatives as CCR4 Antagonists
原文传递
导出
摘要 A series of tri-substituted chiral pyrrolidin-2-one derivatives have been designed and synthesized as CC chemokine receptor 4 (CCR4) antagonists. The structure of CCR4 was built by homology modeling. Asymmetric synthesis was applied to synthesize the R,R configuration chiral pyrrolidin-2-one scaffold. The stereoisomeric con- figurations of the compounds were identified by 2D I H-~H COSY spectroscopy and 1D NOESY spectroscopy. This method was more economical and convenient than traditional X-ray single crystal diffraction. In addition, the inter- actions between these compounds and the N-terminal extracellular tail of CCR4 were studied using capillary zone electrophoresis. The CCR4 chemotaxis inhibition effect was tested in CCR4-transfected HEK293 cells. Several compounds showed potent activities as CCR4 antagonists. Among these compounds, lc is the most active one. Its apparent binding constant of CZE experiment result is (1.569±0.11)× 10s L·mol ^-1, and its percentage inhibition of the HEK293/CCR4 cells migration with the concentration of I gmol·L ^-1 in DMSO is 59%. And compound If has slightly higher affinity to N-terminal of CCR4 according to its apparent binding constant than lb because of the in- troduced ester linkage. Further studies on the mechanism of these compounds are in progress. A series of tri-substituted chiral pyrrolidin-2-one derivatives have been designed and synthesized as CC chemokine receptor 4 (CCR4) antagonists. The structure of CCR4 was built by homology modeling. Asymmetric synthesis was applied to synthesize the R,R configuration chiral pyrrolidin-2-one scaffold. The stereoisomeric con- figurations of the compounds were identified by 2D I H-~H COSY spectroscopy and 1D NOESY spectroscopy. This method was more economical and convenient than traditional X-ray single crystal diffraction. In addition, the inter- actions between these compounds and the N-terminal extracellular tail of CCR4 were studied using capillary zone electrophoresis. The CCR4 chemotaxis inhibition effect was tested in CCR4-transfected HEK293 cells. Several compounds showed potent activities as CCR4 antagonists. Among these compounds, lc is the most active one. Its apparent binding constant of CZE experiment result is (1.569±0.11)× 10s L·mol ^-1, and its percentage inhibition of the HEK293/CCR4 cells migration with the concentration of I gmol·L ^-1 in DMSO is 59%. And compound If has slightly higher affinity to N-terminal of CCR4 according to its apparent binding constant than lb because of the in- troduced ester linkage. Further studies on the mechanism of these compounds are in progress.
出处 《Chinese Journal of Chemistry》 SCIE CAS CSCD 2013年第9期1144-1152,共9页 中国化学(英文版)
基金 This work was financially supported by the National Natural Science Foundation of China,the National Major Science & Technology Specific Project,Young Scientific Research Fund Project for Department of Science and Technology of Jilin Province
关键词 CCR4 antagonists tri-substituted chiral pyrrolidin-2-one derivatives synthesis CCR4 antagonists, tri-substituted chiral pyrrolidin-2-one derivatives, synthesis
  • 相关文献

参考文献14

  • 1Power, C. A.; Meyer, A.; Nemeth, K. J. Biol. Chem. 1995, 270, 19495.
  • 2Imai, T.; Baba, M.; Nishimura, M. J. Biol. Chem. 1997, 272, 15036.
  • 3Imai, T.; Chantry, D.; Raport, C. J. J. Biol. Chem. 1998, 273, 1764.
  • 4Han, W. L.; Lou, Y. X.; Tang, J. M. Biochem. J. 2001, 357, 127.
  • 5Wang, Y.; Zhang, Y.; Yang, X. Life Sci. 2006, 78, 614.
  • 6Kim, S. H.; Cleary, M. M.; Fox, H. S. J. Clin. Invest. 2002, 110, 1675.
  • 7Gangur, V.; Oppenheim, J. J. Ann. Allergy Asthma Immunol. 2000, 84, 569.
  • 8Abi-Younes, S.; Si-Tahar, M.; Luster, A. D. Thromh. Res. 2001, 101, 279.
  • 9Yang, P. T.; Kasai, H.; Zhao, L. J. Clin. Exp. Immunol. 2004, 138, 342.
  • 10Columba-Cabezas, S.; Serafmi, B.; Ambrosini, E. J. Neuroimmunol. 2002,130, 10.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部